Overview
- The study published Tuesday in Nature Metabolism reported that people with mild cognitive impairment who took glucosamine had a 25% higher chance of progressing to Alzheimer's and that dementia patients who took it had about a 25% higher mortality risk.
- Researchers reached those figures by using AI to analyze deidentified UF Health records from 2012–2024 and found roughly 8% of patients with MCI or dementia reported glucosamine use.
- Laboratory work showed glucosamine can cross the blood–brain barrier and feed biochemical pathways that add sugar tags to proteins, a process called hyperglycosylation that worsened memory in Alzheimer’s mouse models.
- Postmortem analysis of human Alzheimer's brain tissue found increased protein sugar‑attachment consistent with the mouse results, but the team stresses the clinical data are observational and do not prove causation.
- Because many older adults take glucosamine for joint pain, the authors say the findings warrant urgent prospective trials and careful clinician‑patient discussions, and no major health agencies have changed guidance based on this single study.